Correlation Between Central Reinsurance and Medigen Biotechnology

Can any of the company-specific risk be diversified away by investing in both Central Reinsurance and Medigen Biotechnology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Central Reinsurance and Medigen Biotechnology into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Central Reinsurance Corp and Medigen Biotechnology, you can compare the effects of market volatilities on Central Reinsurance and Medigen Biotechnology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Central Reinsurance with a short position of Medigen Biotechnology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Central Reinsurance and Medigen Biotechnology.

Diversification Opportunities for Central Reinsurance and Medigen Biotechnology

0.49

Correlation Coefficient

Central Reinsurance  Medigen Biotechnology

Very weak diversification

The 3 months correlation between Central and Medigen is 0.49. Overlapping area represents the amount of risk that can be diversified away by holding Central Reinsurance Corp and Medigen Biotechnology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Medigen Biotechnology and Central Reinsurance is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Central Reinsurance Corp are associated (or correlated) with Medigen Biotechnology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Medigen Biotechnology has no effect on the direction of Central Reinsurance i.e., Central Reinsurance and Medigen Biotechnology go up and down completely randomly.

Pair Corralation between Central Reinsurance and Medigen Biotechnology

Assuming the 90 days trading horizon Central Reinsurance Corp is expected to generate 0.25 times more return on investment than Medigen Biotechnology. However, Central Reinsurance Corp is 3.94 times less risky than Medigen Biotechnology. It trades about 0.06 of its potential returns per unit of risk. Medigen Biotechnology is currently generating about -0.09 per unit of risk. If you would invest  2,575  in Central Reinsurance Corp on September 29, 2024 and sell it today you would earn a total of  15.00  from holding Central Reinsurance Corp or generate 0.58% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Central Reinsurance Corp  vs.  Medigen Biotechnology

Central Reinsurance Corp

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Central Reinsurance Corp has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable basic indicators, Central Reinsurance is not utilizing all of its potentials. The latest stock price fuss, may contribute to near-short-term losses for the sophisticated investors.

Medigen Biotechnology

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Medigen Biotechnology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in January 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.

Pair Trading with Central Reinsurance and Medigen Biotechnology

The main advantage of trading using opposite Central Reinsurance and Medigen Biotechnology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Central Reinsurance position performs unexpectedly, Medigen Biotechnology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medigen Biotechnology will offset losses from the drop in Medigen Biotechnology's long position.

The idea behind Central Reinsurance Corp and Medigen Biotechnology pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.